SCHEMBL2298070

SCHEMBL2298070

C=CCN1C[C@H](c2ccccc2OS(=O)(=O)c2ccccc2)OCC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 4/20 0.36
HTR6 P50406 1/20 0.36
METAP2 P50579 1/20 0.36
METAP1 P53582 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PARL Q9H300 1/20 0.35
HSD17B10 Q99714 1/20 0.34
USP2 O75604 1/20 0.33
TSHR P16473 1/20 0.33
DRD2 P14416 3/20 0.32
DRD1 P21728 3/20 0.32
DRD4 P21917 3/20 0.32
DRD5 P21918 3/20 0.32
DRD3 P35462 3/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HPGD P15428 1/20 0.32
GAA P10253 2/20 0.32
MYC P01106 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2291657 1.00 MEN1 (0.36) MEN1KMT2AALDH1A1HTR6METAP2
SCHEMBL2293508 0.86 HTR6 (0.40) MEN1KMT2AALDH1A1HTR6METAP2
SCHEMBL2294159 0.86 HTR6 (0.40) MEN1KMT2AALDH1A1HTR6METAP2
SCHEMBL2293906 0.85 HPGD (0.38) MEN1KMT2AALDH1A1HTR6METAP2
SCHEMBL2296071 0.85 HPGD (0.38) MEN1KMT2AALDH1A1HTR6METAP2
SCHEMBL2291649 0.83 MAOB (0.39) MEN1KMT2AALDH1A1PARLHSD17B10
SCHEMBL2298064 0.83 MAOB (0.39) MEN1KMT2AALDH1A1PARLHSD17B10
SCHEMBL2295346 0.83 MEN1 (0.37) MEN1KMT2AALDH1A1HTR6L3MBTL1
SCHEMBL2296482 0.83 MEN1 (0.37) MEN1KMT2AALDH1A1HTR6L3MBTL1
SCHEMBL2298994 0.80 MEN1 (0.43) MEN1KMT2AALDH1A1HTR6METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-18 US claimed
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-20 US disclosed
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-13 US disclosed
US-7994315-B2 Intermediate compound for synthesizing pharmaceutical agent and production method thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
EP-2221305-A1 Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent Mitsubishi Tanabe Pharma Corporation (JP) 2010-08-25 EP disclosed
EP-2221304-A1 Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent Mitsubishi Tanabe Pharma Corporation (JP) 2010-08-25 EP disclosed
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 MEN1 1671/4885KMT2A 1798/4885ALDH1A1 1251/4885
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 MEN1 1671/4885KMT2A 1798/4885ALDH1A1 1251/4885
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 MEN1 1671/4885KMT2A 1798/4885ALDH1A1 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.